PATIENTS AND METHODS

The Northern Region Young Persons' Malignant Disease Registry
The NRYPMDR was established in 1968 and covers the Northern Region of England as defined by 1972 Boundary Commission (Compten, 1972) , excluding the district of Barrow-in-Furness. The study region (Figure 1 ) has a population of 3.1 million, with approximately 37 000 live births per year and covers an area of 15 337 km 2 with a mixture of urban and rural areas. Population density varies widely; Northumberland and Cumbria are the two most sparsely populated counties in England, while Tyne & Wear is one of the most densely populated (HMSO, 1996) . The population is predominantly Caucasian and ethnic minorities account for under 2%. Data on malignancies and benign central nervous systems (CNS) tumours in children resident in the region at time of diagnosis have been collected prospectively since 1968 and incidence and survival up to 1982 have been reported previously (Craft et al, 1987) . Cancers in the 15 to 24 year age group for the period 1968 to 1985 were identified retrospectively in 1985 (Craft et al, 1993) and have been collected prospectively since then.
Cases are identified from multiple sources: consultants in the region notify the registry of any malignancies in children and, young adults. Data are periodically cross-checked with regional and national cancer registries; death certificates and hospital admissions are scrutinized regularly. The registry liaises with the National Children's Tumour Registry in Oxford and the United Kingdom Children's Cancer Study Group to ensure information is as accurate and complete as possible. Ascertainment is believed to be at least 98% complete. Responsible clinicians and general practitioners are contacted at regular intervals (approximately 6-monthly) to determine patients' current vital status. The registry does not record cervical intra-epithelial neoplasia.
Data collected by the NRYPMDR include demographic details (such as age, gender, residential address) and details of diagnosis and treatment. A copy of the birth certificate is obtained by the registry and cases undergo central diagnostic and pathological review. Tumours are coded for morphology and primary site using the International Classification of Diseases for Oncology (ICDO-2) (WHO, 1990) . Cases are grouped according to a modified version of the International Classification of Childhood Cancer (ICCC) (Kramarova et al, 1996) . The modifications are as follows:
1. Germ cell and gonadal tumours (group Xc) is subdivided into seminoma (M9060-9064), testicular endodermal tumours (M9070-9079), testicular teratoma (M9080-9102), and germ cell tumours of the ovary. 2. Other carcinomas (group Xf) are subdivided into lung (C34.0-34.9), colorectal (C18.0-20.9), breast (C50.0-50.9), cervix (C53.8-53.9), and other sites 3. Langerhans cell histiocytosis (LCH) is reported as a separate group and not included in further analysis.
Data verification programs are applied to check the validity of morphology, primary site and gender combinations. Second and subsequent primary cancers (51), tumours of benign or uncertain behavior (56) and carcinomas in situ (8) were excluded from the analyses.
Data analysis
Incidence rates were calculated based on mid-year population estimates for the study region obtained from the National Health Service Executive, Durham. Adjustments for the population of Barrow-in-Furness were made based on census estimates. Age-standardized rates (ASR) were calculated based on the standard world population (Smith, 1992) . Cumulative rates and cumulative risks were also calculated (Day, 1992) . Trends for changes in annual ASR were analysed by single linear regression. Survival rates were calculated using Kaplan-Meier estimation (Kaplan and Meier, 1958) .
RESULTS
Incidence
There were 4316 patients aged under 25 years diagnosed with a first cancer in the study region between 1968 and 1995; 2099 (M:F 1.28:1) children (age < 15 years) and 2217 (M:F 1.23:1) young adults (age 15-24 years). In addition there were 46 cases of Langerhans cell histiocytosis (LCH). Number of cases and agespecific incidence rates by disease type for the period 1968-1995 are shown in Table 1 . Of two cases classed as hepatoblastoma in the 20 to 24 year group only one with carcinoid syndrome had central review of pathology; it was compatible with a primary hepatoma though metastases from a distant site could not be completely ruled out. The 'other specified sarcomas' (group IXd) composed of synovial sarcoma (25), leiomyosarcoma (11), soft tissue Ewing's/pPNET (10), hemangiopericytoma (4), myxoid liposarcoma (3), hemangiosarcoma (3), myxosarcoma (2), pleomorphic liposarcoma (2), clear cell sarcoma (2), alveolar soft part sarcoma (2), other unique sarcomas (12). In the non-melanoma skin carcinoma (Group XIe) basal cell carcinoma was the most frequent type (n = 40) with squamous cell carcinoma accounting for six cases. The principle sites of the 'other and unspecified carcinomas' (group XIf5) were carcinoma of unknown primary (ICDO C80.9 n = 18), urethra and other urinary organs (C68 n = 17), salivary glands (C8 n = 10), small intestine (C17 n = 7) and mediastinum (C38 n = 7). The remaining 53 carcinomas were from a heterogeneous range of sites each with fewer than five cases. From 1968 to 1995 there were 32 million person years at risk for the 0 to 24 year age group. The age-standardized rates over the 28-year period for all cancers combined were 121 per million per year (95% confidence interval (CI) 116-126) for children, and 175 per million per year (95% CI 167-183) for young adults. Incidence rates (per million per year) varied by age-group; 167 for infants, 174 for 1-4 years, 91 for 5-9 years, 86 for 10-14 years, 144 for 15-19 years and 209 for 20-24 years. The cumulative incidence rate for cancer up to the age of 25 years was 3511 per million; i.e. a cumulative risk of 1 in 285. The ASR for childhood cancer in males was 131 per million children per year and 110 for females. For young adults (15-24 years) it was 192 for males and 158 for females.
There was a significant increase in the incidence of childhood cancers over the period ( Figure 2) ; overall ASRs increased by 12 per million per decade (P < 0.001). Incidence of cancer in young adults increased over time (Figure 3 ) at a rate of 16 per million per decade (P Ϲ 0.008).
Follow-up
Median follow-up of the 2311 surviving patients was 12 years (range 1-31 years). For 2286 survivors the latest follow-up date was within 2 years of the date of analysis. Of those diagnosed prior to 1992 there were only eight with fewer than 5 years follow-up.
Survival (Figure 4)
Five-year survival rates for children (0-14 years) over the time periods 1968-1977, 1978-1987, 1988-1995 were 42% (95% CI 38-45%), 57% (95% CI 54-61%) and 71% (95% CI 67-75%) respectively. For haematological malignancies 5-year survival rates over the three periods were 30% (95% CI 25-35%), 60% (95% CI 54-65%) and 77% (95% CI 71-82%) respectively. Survival rates for solid tumours were 41% (95% CI 37-46%), 56% (95% CI 51-60%) and 67% (95% CI 63-72%) respectively.
Five-year survival rates for young adults (15-24 years) over the three time periods 1968-1977, 1978-1987, 1988-1995 for all cancers were 45% (95% CI 42-49%), 62% (95% CI 58-65%) and 73% (95% CI 70-78%) respectively. For haematological malignancies 5-year survival rates over the three periods were 44% (95% CI 38-50%), 67% (95% CI 61-71%) and 72% (95% CI 66-78%) respectively. For solid tumours the rates were 46% (95% CI 41-51%), 58% (95% CI 54-62%) and 75% (95% CI 70-79%) respectively.
DISCUSSION
Comprehensive cancer registration is a prerequisite for the effective planning of health services and evaluation of treatment efficacy. It also forms the basis for epidemiological studies which may lead to understanding of the aetiology of cancer. National registries give a broad picture of the situation but their data is 1988-1995 1978-1987 1968-1977 P < 0.001, log-rank test 1988-1995 1978-1987 1968-1977 P < 0.001, log-rank test 1988-1995 1978-1987 1968-1977 P < 0.001, log-rank test 1988-1995 1978-1987 1988-1995 1978-1987 1988-1995 1978-1987 1968-1977 P < 0.001, log-rank test
Survival (%)
Survival ( rarely as detailed or timely as is possible within a local registry. The NRYPMDR was one of the first population-based registries for childhood cancer and is the only registry in the UK having specialist information on the 15 to 24 year age group. It implements rigorous procedures to ensure that ascertainment is as complete as possible; cases are identified from multiple sources. Cancers in children have been registered prospectively from the onset of the registry in 1968 whilst the data on young adults were obtained retrospectively in 1985 in a very comprehensive exercise and have been collected prospectively since then. Small but significant increases in incidence over time are reported for both children and young adults. It is possible that there may have been under-ascertainment of young adults in the early period. However, the steady increase in incidence over time suggests a genuine increase in the underlying incidence of malignant disease (Figure 3 ).
Childhood cancer
There were 2099 cases of cancer registered in children aged 0-14 years over the period 1968-1995 included in this study.
Incidence rates for childhood cancer in the study region are generally similar to those reported by the UK National Registry of Childhood Cancers and to those in other Western populations (Parkin et al, 1988) . The most common type of cancer was acute lymphoblastic leukaemia, accounting for 31% of cases with CNS tumours (23%) and forming the second largest group. This report suggests a small but significant increase in the incidence of childhood cancer in the Northern Region, which is unlikely to be entirely accounted for by under-ascertainment in the early period: registration rates for paediatric cancers are considered to be in excess of 98%. The registry has consistently identified cases from multiple sources and treatment is centralized. Increased incidence is consistent with other population-based reports. Data from the USA indicated trends of increasing incidence of childhood cancer (Gurney et al, 1996) , particularly in infants (Gurney et al, 1998; Kenney et al, 1998) . There have been reports of increased incidence of specific tumours in the UK for neuroblastoma (Stiller, 1993) and leukaemia (Blair and Birch, 1994) . The aetiology of childhood cancers remains largely unknown; only about 5% are thought to have an inherited genetic component (Narod et al, 1991) . The increasing incidence of childhood cancer is consistent with the hypothesis that environmental factors play a role in the aetiology of these diseases. There is considerable evidence that the risk of childhood leukaemia in particular is influenced by characteristics of the environment, such as population mixing (Kinlen, 1995; Dickinson and Partier, 1999) . For solid tumours the route by which the environment influences the risk of disease is unclear. The dramatic improvements in survival over the period mirror national and international trends in outcome (Stiller, 1994) .
Young adults
There is little published specifically concerning cancer incidence and survival in young adults, particularly in 20 to 24 year age group, with a few notable exceptions. This population-based study recorded 2217 cancers diagnosed in young adults. Lymphomas were the largest diagnostic group (26% of cases), with Hodgkin's disease being the most frequent diagnosis. Leukaemias accounted for 13% of cases and the proportions of acute myeloid and chronic myeloid types were higher than in children (38% and 9% vs 14% and 1% respectively).
There have been a small number of other population based reports including 15 to 19 year-olds. A study of cancer in Nordic countries (Tulinius et al, 1992 (Tulinius et al, ) during 1981 (Tulinius et al, -1986 reported that incidence and distribution of cancer types in adolescents were similar to those seen in the North of England. In a study of adolescents (10-19 years) in New South Wales (Fritschi et al, 1995) over the period 1972-1991 incidence in the 15 to 19-year group was higher than in the North of England (rates per million per year: males 202 vs 167 and females 186 vs 121). This difference was largely due to the well known higher incidence of malignant melanoma which accounted for 27% of the Australian cases compared to 5% of cases in the North of England. A report from the SEER programme (Smith et al, 1999) , for 1975-1994 also found higher overall incidence for 15-to 19-year-olds (rates 202 vs 144). Rates were similar for ALL (13 vs 13 per million, per year), AML (9 vs 9), Hodgkin's disease (33 vs 28), CNS (20 vs 23). However, SEER reported higher rates for germ-cell/gonadal (31 vs 13), thyroid cancer (15 vs 4), soft tissue sarcoma (16 vs 9), melanoma (14 vs 7) and NHL (15 vs 10). In common with the North of England the SEER data indicated a trend for increasing incidence of cancers in the 15 to 19 year-olds. Those cancers for which the differences in incidence rates were greatest included tumours which have been reported to be increasing in incidence (testicular cancer, melanoma and NHL) (Brown et al, 1987; Elder, 1995; Cartwright et al, 1999) . Different racial characteristics of the populations may also affect the incidence of some types of cancer. Studies of 10-to 19-year-olds in Denmark (Martos et al, 1993 (Martos et al, ) during 1943 (Martos et al, -1987 and Vaud in Switzerland (Levi et al, 1995) in 1974-1992 also found trends for increasing incidence of cancer in adolescents.
The diverse range of solid tumours in young adults may be categorized into three broad groups: (1) 'late' paediatric type cancers (groups IIIc, IV, VIa, VIIa, IXa), (2) 'age-specific' cancers for adolescents and young adults (groups VIII, Xc), and (3) 'early onset' carcinomas (group XI). The 'late' paediatric cancers normally associated with childhood included rhabdomyosarcoma (26 cases), medulloblastoma (14), neuroblastoma (seven), hepatoblastoma (two) and Wilms' tumour (one). There have been other anecdotal reports of such 'late' paediatric cancers in adult patients (Hollowood and Fletcher, 1994; Hentrich et al, 1995; Paterson and Walker, 1995; Moody et al, 1996; Varona and Ruiz, 1996) . The cancers which are 'largely specific' to adolescents and young adults include bone tumours and testicular cancer. Bone tumours have a peak incidence between the ages of 10 and 20 years and accounted for 6% of cancers in young adults in this series; osteosarcoma and particularly Ewing's sarcoma are less common in patients older than 25 years (Dortman and Czerniak, 1995) . Testicular cancer is most common in men in thier 20s; most of the men in this series had histological diagnoses of teratoma or seminoma while endodermal testicular cancer tended to predominate in boys aged under 15 years. There are many 'early onset' carcinomas arising in a wide range of anatomical sites. These include skin cancer (173 cases) with malignant melanoma being the most common type, thyroid carcinoma (59) and nasopharyngeal carcinoma (14). There are also carcinomas that are considered rare in young adults, particularly carcinomas of the breast (34), cervix (67), gastrointestinal system (43) and lung (16). The aetiology of these 'early onset' carcinomas remains largely unknown, though it is likely that there will be an inherited component.
Survival in the study region has improved considerably over the 28-year period, those diagnosed during 1988-1995 having a 5-year survival rate of 73% (95% CI 70-78). Improvements in survival in young adults have matched those seen in children and suggest that either many of the tumours of early adulthood are intrinsically more curable than those in older adults or that young adults receive more concentrated and effective treatment than is offered to many older adults, or a combination of the two. Those cancers with particularly good prognosis in this age-group include Hodgkin's disease, testicular cancer, thyroid carcinoma and nonmelanoma skin cancer. For the cohort diagnosed between 1988 and 1995 the 5-year survival for Hodgkin's disease was 87%, (95% CI 80-93), testicular cancer 87% (95% CI 81-94), and at time of analysis there had been no deaths from thyroid carcinoma or non-melanoma skin cancers.
The number of survivors of cancer during childhood and early adulthood has increased and in this series 2088 survived at least 5 years. By the year 2025 approximately 1 in 400 of the adult population will be a survivor of cancer diagnosed before the age 25 years. The improvements in survival draw attention to the steadily growing population in whom study of psycho-social and other long-term effects for treatment of cancer is needed. Although there is considerable published and on-going research into late effects of treatment for childhood cancer, less is documented about late effects of treatment given to young adults. Specific studies of the late effects of diagnosis and treatment for cancer in young adults may be needed. The increase in incidence in the Northern region is cause for concern and requires further investigation.
